ES2060199T3 - Forma galenica para administrar oralmente glipicida hipoglicemica. - Google Patents

Forma galenica para administrar oralmente glipicida hipoglicemica.

Info

Publication number
ES2060199T3
ES2060199T3 ES90914370T ES90914370T ES2060199T3 ES 2060199 T3 ES2060199 T3 ES 2060199T3 ES 90914370 T ES90914370 T ES 90914370T ES 90914370 T ES90914370 T ES 90914370T ES 2060199 T3 ES2060199 T3 ES 2060199T3
Authority
ES
Spain
Prior art keywords
glipicide
hypoglycemic
administer orally
gallenic
gallenic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914370T
Other languages
English (en)
Inventor
Anthony L Kuczynski
Atul Devdatt Ayer
Patrick S-L Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ES2060199T3 publication Critical patent/ES2060199T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Telephone Function (AREA)
  • Telephonic Communication Services (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubrication Of Internal Combustion Engines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE PRESENTA UNA FORMA DE DOSIFICACION QUE COMPRENDE LA GLIPICIDA DE DROGA ANTIDIABETICA PARA LA ADMINISTRACION A UN PACIENTE QUE NECESITA UNA TERAPIA DE GLIPICIDA.
ES90914370T 1989-09-05 1990-08-31 Forma galenica para administrar oralmente glipicida hipoglicemica. Expired - Lifetime ES2060199T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/402,314 US5024843A (en) 1989-09-05 1989-09-05 Oral hypoglycemic glipizide granulation

Publications (1)

Publication Number Publication Date
ES2060199T3 true ES2060199T3 (es) 1994-11-16

Family

ID=23591411

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914370T Expired - Lifetime ES2060199T3 (es) 1989-09-05 1990-08-31 Forma galenica para administrar oralmente glipicida hipoglicemica.

Country Status (20)

Country Link
US (2) US5024843A (es)
EP (1) EP0490991B1 (es)
JP (1) JP2919964B2 (es)
KR (1) KR0157640B1 (es)
AT (1) ATE94393T1 (es)
AU (1) AU632859B2 (es)
CA (1) CA2024502C (es)
DE (1) DE69003392T2 (es)
DK (1) DK0490991T3 (es)
ES (1) ES2060199T3 (es)
FI (1) FI104950B (es)
GR (1) GR1000932B (es)
HK (1) HK116897A (es)
IE (1) IE62594B1 (es)
MX (1) MX171191B (es)
NO (1) NO303963B1 (es)
NZ (1) NZ235127A (es)
PT (1) PT95169B (es)
WO (1) WO1991003247A1 (es)
ZA (1) ZA906972B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US6361795B1 (en) * 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
DE69735002T2 (de) * 1996-10-25 2006-10-26 Shire Laboratories, Inc. Osmotisches Verabreichungssystem für lösliche Dosen
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ZA979605B (en) * 1996-11-25 1998-05-21 Alza Corp Ascending-dose dosage form.
EP1782798A3 (en) * 1996-11-25 2008-05-21 Alza Corporation Ascending-dose dosage form
PT946151E (pt) * 1996-11-25 2006-07-31 Alza Corp Forma de dosagem de dose crescente
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
CN1228043C (zh) * 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
WO2001091717A1 (en) * 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Oral delivery form comprising glipizide
AU5459201A (en) * 2000-05-30 2001-12-11 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US7130822B1 (en) * 2000-07-31 2006-10-31 Cognos Incorporated Budget planning
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0213079A (pt) * 2001-09-28 2004-11-09 Sun Pharmaceutical Ind Ltd Forma de dosagem para o tratamento da diabetes mellitus
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1471887B1 (en) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
WO2003096968A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20060002998A1 (en) * 2002-11-15 2006-01-05 Anupam Trehan Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
CN100571783C (zh) * 2006-10-30 2009-12-23 北京红林制药有限公司 格列吡嗪控释片及其制备方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
CN101940578B (zh) * 2010-08-25 2012-07-25 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物及其制备方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
IL326413A (en) 2023-08-08 2026-04-01 United Therapeutics Corp Method for producing an oral pharmaceutical osmotic system and a pharmaceutical batch produced using the same method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
MY102980A (en) * 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US5002772A (en) * 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation

Also Published As

Publication number Publication date
ATE94393T1 (de) 1993-10-15
NO920740L (no) 1992-02-25
CA2024502C (en) 1991-03-06
WO1991003247A1 (en) 1991-03-21
JPH05500222A (ja) 1993-01-21
NZ235127A (en) 1993-02-25
US5545413A (en) 1996-08-13
MX171191B (es) 1993-10-06
AU6417590A (en) 1991-04-08
FI920956A0 (fi) 1992-03-04
NO303963B1 (no) 1998-10-05
AU632859B2 (en) 1993-01-14
CA2024502A1 (en) 1991-03-06
KR0157640B1 (ko) 1998-11-16
KR920703066A (ko) 1992-12-17
IE903166A1 (en) 1991-03-13
JP2919964B2 (ja) 1999-07-19
FI104950B (fi) 2000-05-15
NO920740D0 (no) 1992-02-25
DE69003392T2 (de) 1994-01-13
HK116897A (en) 1997-09-05
GR1000932B (el) 1993-03-16
DK0490991T3 (da) 1993-11-29
DE69003392D1 (de) 1993-10-21
PT95169A (pt) 1991-05-22
IE62594B1 (en) 1995-02-08
EP0490991A1 (en) 1992-06-24
US5024843A (en) 1991-06-18
GR900100659A (en) 1992-01-20
ZA906972B (en) 1991-06-26
EP0490991B1 (en) 1993-09-15
PT95169B (pt) 1998-06-30

Similar Documents

Publication Publication Date Title
ES2060199T3 (es) Forma galenica para administrar oralmente glipicida hipoglicemica.
CA2041579A1 (en) Dosage form
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
NO306377B1 (no) Doseform for avgivelse av et medikament
MX9700081A (es) Composiciones farmaceuticas de tacrina.
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
IT7849462A0 (it) Corpo di capsula in particolare per una capsula per la somministrazione di sostanze medicamentose come pure procedimento e dispositivo per lasua produzione
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
DK349889D0 (da) Anvendelse af polyacrylater til fremstilling af et laegemiddel
PL273790A1 (en) Method of manufacturing means for administering and/or dosing active substances of medicaments
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
ES2043608T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas con acetil-l-carnitina para el tratamiento terapeutico de condicones de shock.
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
RU97101378A (ru) Способ купирования абстинентного синдрома при заболеваниях, связанных с зависимостью от психоактивных веществ
SE8704081D0 (sv) A new prohylactic method
ES2096081T3 (es) Utilizacion de interleuquina 10 para la preparacion de medicamentos con una actividad inhibidora de tumores.
CO5170404A1 (es) Terapia para melanomas
DK493887A (da) Buccal formulering
KR910015299A (ko) 우울증 치료방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490991

Country of ref document: ES